A Phase 2 interventional study of BHV-7000 and BHV-7000 in Focal Epilepsy, sponsored by Biohaven Therapeutics Ltd.. Enrolling by invitation at 283 sites in 27 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Biohaven Therapeutics Ltd. · Phase 2, Interventional, and Treatment
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
254 studies on the registry are indexed under Epilepsies, Partial; 48 are open to participants now.
This study's planned enrollment of 660 is above the median of 87 across 197 interventional studies indexed under Epilepsies, Partial.
Browse Epilepsies, Partial studies →Biohaven Therapeutics Ltd. is the lead sponsor of 19 studies on the registry; 9 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Drug: BHV-7000
Drug: BHV-7000
BHV-7000 50 mg. Participants will take open-label investigational product (IP) once daily
BHV-7000 75 mg. Participants will take open-label investigational product (IP) once daily
Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEs
To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with deaths, SAEs, AEs leading to discontinuation, and moderate and severe AEs.
Time frame: Up to 104 weeks
Number of Subjects with Clinically Significant Laboratory Abnormalities
To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with grade 3 or 4 laboratory abnormalities.
Time frame: Up to 104 weeks
Showing the first 100 of 283 sites across 27 countries.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biohaven Therapeutics Ltd.